MNTA. Indeed it's seperate. I was trying to imagine if an even broader deal could be possible beyond biologics but insofar Sandoz controls both Lovenox and Glatopa i can't really see how. If things were to go in mnta's favor in enox litigation, or even with just the current state of litigation i wonder if it might not be so easy for AGN to offload its product. Can't sell it can't pass it to Teva, can't just pull it off the market. Can you think of a deal that Teva and AGN could offer to MNTA that would make sense?
Market Data 
Markets 
AI
